Ocular Therapeutix (OCUL) is drawing fresh attention as investors look ahead to upcoming April conferences, where the company plans to share additional analyses from its pivotal Phase 3 SOL-1 trial of AXPAXLI.

At a share price of US$8.49, Ocular Therapeutix has seen a 1-day share price return of 1.92% and 7-day share price return of 5.20%. The 30-day share price return of 21.10% and year to date share price return of 28.17% are being considered alongside the 1-year total shareholder return of 21.29% and 3-year total shareholder return of 64.53%, as investors weigh recent SOL-1 data updates and upcoming conference presentations.

If you are interested in other eye and biotech related names riding similar clinical and technology themes, it could be a good time to scan 37 healthcare AI stocks

With annual revenue growth of 48.59% alongside a net loss of US$265.939 million, a value score of 2, and a share price far below some published targets, is OCUL still mispriced or already reflecting future growth expectations?

Most Popular Narrative: 67.3% Undervalued

With Ocular Therapeutix last closing at $8.49 versus a most followed fair value of $26, the current price sits well below that narrative anchor.

The anticipated approval of AXPAXLI, potentially the first wet AMD product with a superiority label and longer dosing intervals (every 6–12 months), may allow Ocular Therapeutix to capture significant market share in a rapidly growing population of elderly patients with retinal disease, unlocking large revenue growth opportunities as the global prevalence of ophthalmic disorders increases.

Curious what kind of revenue ramp, margin shift, and future earnings multiple are being baked into that $26 figure? The narrative leans on aggressive expansion assumptions, a sharp profitability swing, and a premium valuation usually reserved for market leaders.

Result: Fair Value of $26 (UNDERVALUED)

However, this hinges heavily on Axpaxli. Any clinical or regulatory stumble, or weaker real world adoption than trial data implies, could quickly challenge that $26 narrative.

Another View: Multiples Point the Other Way

That $26 fair value hinges on rich earnings assumptions, but the current P/S of 35.6x tells a different story. It sits far above the US Pharmaceuticals average of 4.6x and a fair ratio of just 0.2x, which suggests a wide valuation gap and plenty of room for sentiment to swing. Is the market overpaying for the story or underestimating future cash flows?

For a closer look at what this pricing gap might mean in practice, including how the current ratio compares with what the fair ratio implies over time, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With such a mixed picture on valuation and future expectations, it makes sense to move quickly, test the assumptions against the numbers, and decide where you stand using the 2 key rewards and 4 important warning signs.

Looking for more investment ideas?

If OCUL has your attention, do not stop here. The next strong idea could already fit your style if you widen the search with a few targeted stock lists.

• Kick start your hunt for value by checking companies that combine quality fundamentals with attractive pricing using the 62 high quality undervalued stocks.
• Prioritise resilience and sleep better at night by reviewing the 67 resilient stocks with low risk scores and see which names score well on stability.
• Spot opportunities the crowd has not fully focused on yet by scanning the screener containing 25 high quality undiscovered gems before others catch on.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.